Document is current
Any future updates will be listed below
-
Authors
Hsu, Jonathan Y. https://orcid.org/0000-0002-1342-5628
Grünewald, Julian https://orcid.org/0000-0001-7537-7505
Szalay, Regan https://orcid.org/0000-0002-5438-1596
Shih, Justine
Anzalone, Andrew V.
Lam, Kin Chung
Shen, Max W. https://orcid.org/0000-0002-4226-1861
Petri, Karl https://orcid.org/0000-0002-9624-3976
Liu, David R.
Joung, J. Keith https://orcid.org/0000-0001-5630-5645
Pinello, Luca https://orcid.org/0000-0003-1109-3823
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R00HG008399, R35HG010717, RM1HG009490)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
- License Information
-
More Information
Article History
Received: 18 November 2020
Accepted: 13 January 2021
First Online: 15 February 2021
Change Date: 3 March 2021
Change Type: Update
Change Details: In the original version of this Article, the given and family names of author J. Keith Joung were incorrectly tagged, leading to incorrect indexing. This error has now been corrected. The PDF and HTML versions displayed the name correctly at the time of publication.
Competing interests
: J.K.J. has financial interests in Beam Therapeutics, Chroma Medicine (f/k/a YKY, Inc.), Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, SeQure Dx, Inc., Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a co-inventor on patents and patent applications that describe various gene editing technologies. D.R.L. is a consultant and co-founder of Prime Medicine, Beam Therapeutics, Pairwise Plants, and Editas Medicine, companies that use genome editing. L.P. has financial interests in Edilytics and SeQure Dx, Inc. L.P.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. All other authors declare no competing interests.
